📷 Image Credits: CNBCTV18
Emcure Pharmaceuticals is set to launch its initial public offering (IPO) in July, aiming to raise a total of ₹1,951.04 crore through the issue, considering the upper end of the price band. The IPO is a book built issue of Rs 1,952.03 crores, including a fresh issue of 0.79 crore shares and an offer for sale of 1.14 crore shares.
The Emcure Pharma IPO is scheduled to open for subscription on July 3, 2024, and will close on July 5, 2024. The allotment is expected to be finalized on July 8, 2024, with a tentative listing date fixed as July 10, 2024. The price band for the IPO is set at ₹960 to ₹1008 per share, with a minimum lot size of 14 shares.
Emcure Pharmaceuticals, an Indian pharmaceutical company established in 1981, manufactures and globally markets a wide range of pharmaceutical products across various therapeutic areas. The company is ranked 13th in domestic sales and holds the 4th market share in covered markets. It is a leading player in gynaecology and HIV antiviral therapeutic areas.
With 13 manufacturing facilities in India, Emcure Pharma can produce a variety of pharmaceutical and biopharmaceutical products. The company’s revenue increased by 11.33% in the financial year ending March 2024, with a market capitalization of Rs 19029.89 Cr.
Investors looking to participate in the Emcure Pharma IPO can bid for a minimum of 14 shares and in multiples thereof. Retail investors are required to invest a minimum of ₹14,112, while other categories have specific lot size requirements. The IPO is led by Kotak Mahindra Capital Company Limited, Axis Capital Limited, J.P. Morgan India Private Limited, and Jefferies India Private Limited as the book running lead managers.
Considering the growth prospects and financial performance of Emcure Pharmaceuticals, potential investors are advised to conduct thorough research and consult with financial experts before making any investment decisions.
